Jim Simons’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Jim Simons’s Portfolio OREX Stock Details OREX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-54,950	Closed	-$236K	–	3685
2016 Q2	$236K	Sell	54,950 -183,160	-77%	-$828K	﹤0.01%	3003
2016 Q1	$1.34M	Buy	238,110 +61,490	+35%	+$799K	﹤0.01%	2440
2015 Q4	$3.04M	Sell	176,620 -101,418	-36%	-$2.42M	0.01%	1829
2015 Q3	$5.87M	Buy	278,038 +235,998	+561%	+$8.09M	0.01%	1271
2015 Q2	$2.08M	Buy	+42,040	New	+$2.51M	﹤0.01%	2038

Other funds holding OREX

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Jim Simons's OREX Position: Q3 2016 in Review

Jim Simons sold out of Orexigen Therapeutics, Inc. (OREX) in Q3 2016, closing a stake of 54,950 shares — an estimated $236K sold.

Jim Simons first reported a position in OREX in Q2 2015 and held it in 5 quarters. The position peaked at $5.87M in Q3 2015. 55 funds tracked by Wall St. Rank hold OREX as of Q3 2016.

Jim Simons reported no remaining Orexigen Therapeutics, Inc. position as of Q3 2016 after selling out during the quarter.
Jim Simons sold 54,950 Orexigen Therapeutics, Inc. shares in Q3 2016, an estimated $236K.
Jim Simons first reported a position in Orexigen Therapeutics, Inc. in Q2 2015 and held it in 5 quarters.
Jim Simons's Orexigen Therapeutics, Inc. position peaked at $5.87M in Q3 2015.
55 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q3 2016.

Based on Renaissance Technologies's 13F filing for Q3 2016, filed 14 Nov 2016.